Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia
AMERICAN JOURNAL OF HEMATOLOGY (2015)
期刊
AMERICAN JOURNAL OF HEMATOLOGY
卷 90, 期 2, 页码 120-124出版社
WILEY-BLACKWELL
关键词
类别
资金
- Sigma Tau Pharmaceuticals, Inc.
- National Institutes of Health through MD Anderson's Cancer Center [CA016672]
作者
我是这篇论文的作者
推荐
Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932
Anne L. Angiolillo, Reuven J. Schore, John A. Kairalla, Meenakshi Devidas, Karen R. Rabin, Patrick Zweidler-McKay, Michael J. Borowitz, Brent Wood, Andrew J. Carroll, Nyla A. Heerema, Mary V. Relling, Johann Hitzler, Ashley R. Lane, Kelly W. Maloney, Cindy Wang, Mylene Bassal, William L. Carroll, Naomi J. Winick, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger
JOURNAL OF CLINICAL ONCOLOGY (2021)
Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial
Kun-yin Qiu, Jia-yi Wang, Li-bin Huang, Chang-gang Li, Lu-hong Xu, Ri-yang Liu, Hui-qin Chen, Yong-sheng Ruan, Zi-jun Zhen, Chi-kong Li, Jian-pei Fang
AMERICAN JOURNAL OF HEMATOLOGY (2023)
Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Luke Maese, Rachel E. Rau
FRONTIERS IN PEDIATRICS (2022)
Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Manon Queudeville, Anthony S. Stein, Franco Locatelli, Martin Ebinger, Rupert Handgretinger, Nicola Goekbuget, Lia Gore, Yi Zeng, Priya Gokani, Gerhard Zugmaier, Hagop M. Kantarjian
CANCER (2023)
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
P. G. Richardson, S. Trudel, R. Popat, M- Mateos, A. J. Vangsted, K. Ramasamy, J. Martinez-Lopez, H. Quach, R. Z. Orlowski, M. Arnao, S. Lonial, C. Karanes, C. Pawlyn, K. Kim, A. Oriol, J. G. Berdeja, P. Rodriguez Otero, I Casas-Aviles, A. Spirli, J. Poon, S. Li, J. Gong, L. Wong, M. Lamba, D. W. Pierce, M. Amatangelo, T. Peluso, P. Maciag, J. Katz, Michael Pourdehnad, Nizar J. Bahlis
NEW ENGLAND JOURNAL OF MEDICINE (2023)
CD38-Directed Vincristine Nanotherapy for Acute Lymphoblastic Leukemia
Yifan Zhang, Jingnan An, Yu Shao, Na Yu, Shujing Yue, Huanli Sun, Jubin Zhang, Wenxing Gu, Yifeng Xia, Jinping Zhang, Yang Xu, Zhiyuan Zhong
BIOMACROMOLECULES (2022)
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
Shai Shimony, Yiwen Liu, Yannis K. Valtis, Jonathan D. Paolino, Andrew E. Place, Andrew M. Brunner, Lachelle D. Weeks, Lewis B. Silverman, Lynda M. Vrooman, Donna S. Neuberg, Richard M. Stone, Daniel J. DeAngelo, Marlise R. Luskin
BLOOD ADVANCES (2023)
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
Max S. Topp, Nicola Goekbuget, Gerhard Zugmaier, Anthony S. Stein, Herve Dombret, Yuqi Chen, Josep-Maria Ribera, Ralf C. Bargou, Heinz-August Horst, Hagop M. Kantarjian
CANCER (2021)
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia
Wendy Stock, Giovanni Martinelli, Matthias Stelljes, Daniel J. DeAngelo, Nicola Goekbuget, Anjali S. Advani, Susan O'Brien, Michaela Liedtke, Akil A. Merchant, Ryan D. Cassaday, Tao Wang, Hui Zhang, Erik Vandendries, Elias Jabbour, David Marks, Hagop M. Kantarjian
CANCER (2021)
Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions
Sima Jeha
INDIAN JOURNAL OF PEDIATRICS (2023)
Venetoclax and navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Vinod A. Pullarkat, Norman J. Lacayo, Elias Jabbour, Jeffrey E. Rubnitz, Ashish Bajel, Theodore W. Laetsch, Jessica Leonard, Susan Colace, Seong Lin Khaw, Shaun A. Fleming, Ryan J. Mattison, Robin Norris, Joseph T. Opferman, Kathryn G. Roberts, Yaqi Zhao, Chunxu Qu, Mohamed Badawi, Michelle Schmidt, Bo Tong, John C. Pesko, Yan Sun, Jeremy A. Ross, Deeksha Vishwamitra, Lindsey Rosenwinkel, Su Young Kim, Amanda Jacobson, Charles G. Mullighan, Thomas B. Alexander, Wendy Stock
CANCER DISCOVERY (2021)
Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
Jia Zhu, Juan Wang, Feifei Sun, Zijun Zhen, Tingting Chen, Suying Lu, Junting Huang, Yizhuo Zhang, Xiaofei Sun
FRONTIERS IN ONCOLOGY (2022)
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
Edoardo Pennesi, Naomi Michels, Erica Brivio, Vincent H. J. van der Velden, Yilin Jiang, Adriana Thano, Anneke J. C. Ammerlaan, Judith M. Boer, H. Berna Beverloo, Barbara Sleight, Ying Chen, Britta Vormoor-Buerger, Susana Rives, Bella Bielorai, Claudia Roessig, Arnaud Petit, Carmelo Rizzari, Gernot Engstler, Jan Stary, Francisco J. Bautista Sirvent, Christiane Chen-Santel, Benedicte Bruno, Yves Bertrand, Fanny Rialland, Genevieve Plat, Dirk Reinhardt, Luciana Vinti, Arend Von Stackelberg, Franco Locatelli, Christian M. Zwaan
LEUKEMIA (2022)
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
Talha Badar, Aniko Szabo, Shira Dinner, Michaela Liedtke, Madelyn Burkart, Rory M. Shallis, Ilana R. Yurkiewicz, Eric Kuo, Muhammad Ali Khan, Suresh Balasubramanian, Jay Yang, Mehrdad Hefazi, Nikolai Podoltsev, Anand Patel, Emily Curran, Amy Wang, Shukaib Arslan, Ibrahim Aldoss, Caitlin Siebenaller, Ryan J. Mattison, Mark R. Litzow, Martha Wadleigh, Anjali S. Advani, Ehab Atallah
CANCER (2021)
Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
Anna Ferrari, Delia Cangini, Andrea Ghelli Luserna di Rora, Annalisa Condorelli, Marta Pugliese, Giovanni Schinina, Sebastiano Cosentino, Eugenio Fonzi, Chiara Domizio, Giorgia Simonetti, Salvatore Leotta, Giuseppe Milone, Giovanni Martinelli
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2023)
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J. Schiller, Shira N. Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang, Karen P. Seiter, Andrew H. Wei, Stephane De Botton, Montserrat Arnan, Will Donnellan, Anthony P. Schwarer, Christian Recher, Brian A. Jonas, P. Brent Ferrell Jr, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M. Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jorge E. Cortes
LANCET HAEMATOLOGY (2023)
Low dose thymoglobulin versus basiliximab in cytomegalovirus positive kidney transplant recipients: Effectiveness of preemptive cytomegalovirus modified strategy
Camilo Montero, Nancy Yomayusa, Rodolfo Torres, Jorge Cortes, Carlos Alvarez, Juan Gallo, Guillermo Aldana, Andres Acevedo, Maria Rios, Johana Echeverri, Zuly Yepes, Adriana Silva, Diana Gayon, Jorge Perez, Milciades Ibanez
NEFROLOGIA (2023)
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
Michael J. Mauro, Timothy P. Hughes, Dong-Wook Kim, Delphine Rea, Jorge E. Cortes, Andreas Hochhaus, Koji Sasaki, Massimo Breccia, Moshe Talpaz, Oliver Ottmann, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Michael C. Heinrich, Valle Gomez-Garcia de Soria, Philipp le Coutre, Francois-Xavier Mahon, Jeroen J. W. M. Janssen, Michael Deininger, Naranie Shanmuganathan, Mark B. Geyer, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Matthias Hoch, Fabian Lang
LEUKEMIA (2023)
Representation of the population in need for pivotal clinical trials in lymphomas
Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Mahran Shoukier, K. M. Islam, Jorge Cortes
BLOOD (2023)
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia
Fabio Efficace, Francesco Cottone, Betina Yanez, Vamsi Kota, Fausto Castagnetti, Giovanni Caocci, Massimiliano Bonifacio, Andrea Patriarca, Isabella Capodanno, Maria Cristina Miggiano, Mario Tiribelli, Massimo Breccia, Luigia Luciano, Valentina Giai, Alessandra Iurlo, Elisabetta Abruzzese, Carmen Fava, Shira Dinner, Jessica K. Altman, Gianantonio Rosti, Jorge Cortes, Marco Vignetti, David Cella
CANCER (2023)
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
Koji Sasaki, Kiyomi Morita, Hagop Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, William Wierda, Naval Daver, Koichi Takahashi, Courtney Dinardo, Guillermo Montalban Bravo, Ghayas C. Issa, Sherry A. Pierce, Kelly A. Soltysiak, Martha S. Tingen, Jorge E. Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)
Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers
Pankaj Ahluwalia, Ashutosh Vashisht, Harmanpreet Singh, Nikhil Shri Sahajpal, Ashis K. Mondal, Kimya Jones, Jaspreet Farmaha, Ryan Bloomquist, Caroline Marie Carlock, Drew Fransoso, Christina Sun, Tyler Day, Comfort Prah, Trinh Vuong, Patty Ray, Danielle Bradshaw, Marisol Miranda Galvis, Sadanand Fulzele, Girindra Raval, Justin Xavier Moore, Jorge Cortes, Jeffrey N. James, Vamsi Kota, Ravindra Kolhe
JOURNAL OF MEDICAL VIROLOGY (2023)
Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review
Marisol Miranda-Galvis, Kellen C. Tjioe, E. Andrew Balas, Gagan Agrawal, Jorge E. Cortes
BLOOD ADVANCES (2023)
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
Mahesh Swaminathan, Jorge E. E. Cortes
THERAPEUTIC ADVANCES IN HEMATOLOGY (2023)
Outcomes with bosutinib vs. imatinib by Charlson Comorbidity Index in patients with chronic myeloid leukaemia
Gemma Shay, Michael W. Deininger, Tim H. Bruemmendorf, Jeffrey H. Lipton, Leif Stenke, Eric Leip, Simon Purcell, Andrea Viqueira, Jorge E. Cortes
BRITISH JOURNAL OF HAEMATOLOGY (2023)
Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial
Richard F. Schlenk, Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elzbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Herve Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, Harry P. Erba
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)
Define the Vulnerable - Social Determinants of Health Impact on Hematological Malignancies Affecting Children, Adolescents, and Young Adults: Systematic Review and Meta-Analysis
Muhannad Sharara, Kellen Cristine Tjioe, Marisol Miranda Galvis, Gagan Agrawal, Andrew Balas, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)
T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML)
Aram Bidikian, Sreyashi Basu, Zhong He, Himachandana Atluri, Jabra Zarka, Michael Andreeff, Koji Sasaki, Elias Jabbour, Jorge E. Cortes, Padmanee Sharma, Ghayas C. Issa
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)
The Importance of Quality of Survivorship: US Results From the Chronic Myeloid Leukemia (CML) Survey on Unmet Needs (SUN)
Joannie Clements, Cristina Ruiz, Andrea Damon, Peter Schuld, Pauline Frank, Cristina Constantinescu, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)
Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane Apperley
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)